Literature DB >> 29515039

Physiological mechanisms of sustained fumagillin-induced weight loss.

Jie An1, Liping Wang1, Michael L Patnode2,3, Vanessa K Ridaura2,3, Jonathan M Haldeman1, Robert D Stevens1, Olga Ilkayeva1, James R Bain1, Michael J Muehlbauer1, Erin L Glynn1, Steven Thomas1, Deborah Muoio1, Scott A Summers1, James E Vath4, Thomas E Hughes4, Jeffrey I Gordon2,3, Christopher B Newgard1.   

Abstract

Current obesity interventions suffer from lack of durable effects and undesirable complications. Fumagillin, an inhibitor of methionine aminopeptidase-2, causes weight loss by reducing food intake, but with effects on weight that are superior to pair-feeding. Here, we show that feeding of rats on a high-fat diet supplemented with fumagillin (HF/FG) suppresses the aggressive feeding observed in pair-fed controls (HF/PF) and alters expression of circadian genes relative to the HF/PF group. Multiple indices of reduced energy expenditure are observed in HF/FG but not HF/PF rats. HF/FG rats also exhibit changes in gut hormones linked to food intake, increased energy harvest by gut microbiota, and caloric spilling in the urine. Studies in gnotobiotic mice reveal that effects of fumagillin on energy expenditure but not feeding behavior may be mediated by the gut microbiota. In sum, fumagillin engages weight loss-inducing behavioral and physiologic circuits distinct from those activated by simple caloric restriction.

Entities:  

Keywords:  Behavior; Intermediary metabolism; Metabolism; Obesity; Therapeutics

Mesh:

Substances:

Year:  2018        PMID: 29515039      PMCID: PMC5922281          DOI: 10.1172/jci.insight.99453

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  28 in total

1.  Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB.

Authors:  T Z DeSantis; P Hugenholtz; N Larsen; M Rojas; E L Brodie; K Keller; T Huber; D Dalevi; P Hu; G L Andersen
Journal:  Appl Environ Microbiol       Date:  2006-07       Impact factor: 4.792

2.  The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.

Authors:  N Sin; L Meng; M Q Wang; J J Wen; W G Bornmann; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 3.  Effects of ingestion of disproportionate amounts of amino acids.

Authors:  A E Harper; N J Benevenga; R M Wohlhueter
Journal:  Physiol Rev       Date:  1970-07       Impact factor: 37.312

4.  Ablation of dihydroceramide desaturase 1, a therapeutic target for the treatment of metabolic diseases, simultaneously stimulates anabolic and catabolic signaling.

Authors:  Monowarul M Siddique; Ying Li; Liping Wang; Jianhong Ching; Mainak Mal; Olga Ilkayeva; Ya Jun Wu; Boon Huat Bay; Scott A Summers
Journal:  Mol Cell Biol       Date:  2013-04-01       Impact factor: 4.272

5.  Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial.

Authors:  Shawn E McCandless; Jack A Yanovski; Jennifer Miller; Cary Fu; Lynne M Bird; Parisa Salehi; Christine L Chan; Diane Stafford; M Jennifer Abuzzahab; David Viskochil; Sarah E Barlow; Moris Angulo; Susan E Myers; Barbara Y Whitman; Dennis Styne; Elizabeth Roof; Elisabeth M Dykens; Ann O Scheimann; Jaret Malloy; Dongliang Zhuang; Kristin Taylor; Thomas E Hughes; Dennis D Kim; Merlin G Butler
Journal:  Diabetes Obes Metab       Date:  2017-07-13       Impact factor: 6.577

6.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.

Authors:  Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey
Journal:  Cell Metab       Date:  2009-04       Impact factor: 27.287

Review 7.  Long-term drug treatment for obesity: a systematic and clinical review.

Authors:  Susan Z Yanovski; Jack A Yanovski
Journal:  JAMA       Date:  2014-01-01       Impact factor: 56.272

8.  Clock gene expression in the murine gastrointestinal tract: endogenous rhythmicity and effects of a feeding regimen.

Authors:  Willemijntje A Hoogerwerf; Helen L Hellmich; Germaine Cornélissen; Franz Halberg; Vahakn B Shahinian; Jonathon Bostwick; Tor C Savidge; Vincent M Cassone
Journal:  Gastroenterology       Date:  2007-07-12       Impact factor: 22.682

9.  Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states.

Authors:  Michael K Badman; Pavlos Pissios; Adam R Kennedy; George Koukos; Jeffrey S Flier; Eleftheria Maratos-Flier
Journal:  Cell Metab       Date:  2007-06       Impact factor: 27.287

10.  Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor 2-associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases.

Authors:  Bansidhar Datta; Avijit Majumdar; Rekha Datta; Ramesh Balusu
Journal:  Biochemistry       Date:  2004-11-23       Impact factor: 3.162

View more
  3 in total

1.  MetAP2 inhibition reduces food intake and body weight in a ciliopathy mouse model of obesity.

Authors:  Tana S Pottorf; Micaella P Fagan; Bryan F Burkey; David J Cho; James E Vath; Pamela V Tran
Journal:  JCI Insight       Date:  2020-01-30

2.  MetAP2 inhibitor treatment of high-fat and -fructose-fed dogs: impact on the response to oral glucose ingestion and a hyperinsulinemic hyperglycemic clamp.

Authors:  Mary Courtney Moore; Katie C Coate; Melanie Scott; Guillaume Kraft; James E Vath; Thomas E Hughes; Ben Farmer; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-01-28       Impact factor: 4.310

Review 3.  Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss.

Authors:  Berit Østergaard Christoffersen; Guillermo Sanchez-Delgado; Linu Mary John; Donna H Ryan; Kirsten Raun; Eric Ravussin
Journal:  Obesity (Silver Spring)       Date:  2022-04       Impact factor: 9.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.